INO

NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Inovio Pharmaceuticals caused the company to misrepresent or fail to disclose that (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated.

Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Inovio Pharmaceuticals caused the company to misrepresent or fail to disclose that (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated.

PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific and investor conferences: Jefferies Global Healthcare Conference (New York) Date: Thursday, June 4 Time: 8:45 AM ET Format: Fireside Chat Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/adRiTkvKf4AnDsZYyXatz8  World Orphan Drug Congress (Boston) Poster Presentation: Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine Date: Thursday, June 11 Time: 12:00 – 12:10 PM ET A replay of the investor event will be available for 90 days at the link above.

Inovio Pharmaceuticals NASDAQ: INO shareholders approved all proposals presented at the company's 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending Dec. 31, 2026.

Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by infection with various strains of the human papillomavirus (HPV), eliminating or reducing the need for surgical interventions PLYMOUTH MEETING, Pa., May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia.

Inovio Pharmaceuticals remains a high-risk, event-driven play, with the investment case dominated by the binary FDA decision for INO-3107 in October. Cost discipline has improved, with operating expenses down to $21.9M and cash projected to fund operations into 1Q27, reducing near-term dilution risk. INO-3107 offers a differentiated, patient-friendly profile versus PAPZIMEOS, targeting a potentially larger-than-expected RRP population and non-responders.

Inovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call Transcript

Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial readiness plans continue to advance in anticipation of a potential commercial launch for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis (RRP) Clinical trial collaboration and supply agreement announced with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of glioblastoma (GBM) in a Dana-Farber Cancer Institute-sponsored trial Current cash, cash equivalents, and short-term investments anticipated to fund operations into first quarter 2027, beyond the target PDUFA date PLYMOUTH MEETING, Pa., May 13, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter ended March 31, 2026 and provided an update on recent company developments.

Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.